Business Context and Reporting Period
Company: Anteris Technologies Global Corp. (AVR)
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2026
Business Overview: Anteris is a structural heart company focused on the development and commercialization of the DurAVR® Transcatheter Heart Valve (THV) System. The company is currently advancing the PARADIGM Trial, a global pivotal study intended to support Premarket Approval (PMA) in the U.S. and CE Mark approval in Europe. The company operates as a single reportable segment.
Key Financial Metrics
| Metric (in thousands, except per share) | Q1 2026 | Q1 2025 |
|---|---|---|
| Net Sales | $494 | $556 |
| Operating Loss | $(24,007) | $(21,780) |
| Net Loss (Stockholders) | $(23,024) | $(21,864) |
| Loss Per Share (Basic & Diluted) | $(0.28) | $(0.61) |
| Research & Development Expense | $(17,457) | $(16,456) |
| SG&A Expense | $(6,930) | $(5,673) |
| Cash, Cash Equivalents & Restricted Cash | $283,210 | $12,576 |
| Net Cash Used in Operating Activities | $(28,680) | $(21,489) |
| Net Cash Provided by Financing Activities | $299,511 | $(1,091) |
Material Changes vs. Prior Period
- Liquidity Transformation: Cash balances surged from $12.6 million to $283.2 million, driven by a $320 million gross capital raise in January 2026 (comprising a public offering and a private placement with Medtronic).
- Revenue Decline: Net sales decreased 11% to $0.5 million. This reflects the expiration of the Transition Services Agreement with LeMaitre in January 2025, partially offset by increased sales to 4C Medical Technologies.
- Expense Growth: R&D expenses increased 6% to $17.5 million due to manufacturing upscaling and PARADIGM Trial activities. SG&A increased 22% to $6.9 million due to higher personnel and stock-based compensation costs.
- Non-Operating Income: Other non-operating income increased significantly to $1.7 million (from $0.1 million) due to interest earned on the newly raised capital.
- Share Count: Outstanding shares increased from approximately 41.6 million to 97.2 million following the January 2026 issuances.
Outlook, Risks, and Unusual Items
- Clinical Milestones: The company secured U.S. Medicare reimbursement eligibility for the PARADIGM Trial in April 2026. First patients were enrolled and treated in May 2026.
- Capital Sufficiency: Management believes current cash resources are sufficient to meet operating requirements for at least the next 12 months.
- Subsequent Events:
- Entered a new lease for office/warehouse space in Brooklyn Park, MN (commencing Sept 2026), secured by a $3.5 million letter of credit.
- Terminated the Contribution and Stock Purchase Agreement with v2vmedtech, incurring a $0.4 million break fee but eliminating future funding obligations.
- Internal Controls: The company disclosed material weaknesses in internal control over financial reporting (lack of documented procedures and segregation of duties) that remained unremediated as of March 31, 2026, though a remediation plan is in progress.
- Risk Factors: Significant risks include the potential failure of the PARADIGM Trial, inability to obtain FDA PMA, and the need for additional capital to fund future operations.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $28.7 million quarterly operating cash burn against the $283 million cash balance.
- Revenue Trajectory: Confirm the timeline for the expiration of the 4C Medical Technologies agreement (June 2026) and the lack of near-term commercial revenue from the DurAVR® THV.
- Internal Control Remediation: Monitor progress on remediation of material weaknesses in financial reporting controls.
- Clinical Trial Progress: Track patient enrollment rates and data readouts from the PARADIGM Trial.
- Dilution Impact: Assess the impact of the 55.6 million shares issued in Q1 2026 on future earnings per share.